Similarly in treated macrophages, osimertinib did not cause murine type-I IFN production, however, when macrophages were co-cultured with osimertinib-treated tumor cells, we observed a significant increase in type-I IFN production by macrophages (Fig. 6B), suggesting that macrophages require tumor cells as a source of cGAMP to activate STING. This evidence concerns the gene STING1 and neoplasm.